

PATIENT

Patient: SAMPLE PATIENT
DOB/Sex:
MR/Chart #:
Accession #:

SPECIMEN

Specimen: 1 PB NA HEP
Collected: 6/19/2011
Received: 6/20/2011
All Specimens: 2 PB NA HEP, 1 PB EDTA

PHYSICIAN

SAMPLE DOCTOR
Copies:
REPORT DATE: 6/22/2011

Clinical History:

Hepatosplenomegaly, nonpathologically enlarged lymph hilar, peripancreatic lymph nodes, and leukocytosis with thrombocytopenia.

INTERPRETATION:

Abnormal clone with IGH/BCL1 fusion, monosomy 13, and del(17p)

FISH PROBES AND RESULTS:


(BCL1x3),(IGHx3),(BCL con IGHx2)[58/200]	29% Abnormal
(ATMx2)[200]	Normal
(SE12x2, GLI1x2)[200]	Normal
(DLEU1x1, 13qterx1)[33/200]	16% Abnormal
(p53x2)[43/200]	21% Abnormal

SUMMARY OBSERVATION:


Fluorescence in situ hybridization (FISH)* with a panel of probes (Kreatech) specific for detection of recurring chromosome abnormalities was performed on uncultured peripheral blood cells. The regions/ loci represented in these probe mixes were a IGH/BCL1 probe to detect t(11;14) [specific for Mantle Cell Lymphoma], ATM at 11q22.3 and p53 at 17p13.1 to detect copy number of these loci, SE12 and GLI to detect copy number of chromosome 12, DLEU1 at 13q14, and 13qter to detect deletion/ loss of chromosome 13. Loss of 17p with complex abnormalities is associated with poor outcome in patients with Mantle Cell Lymphoma.

*" This test was developed and its performance characteristics determined by the Cytogenetics laboratory at OncoMetrix as required by the CLIA' 88 regulations. It has not been cleared or approved for specific uses by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research."

IMAGES:



BCL1/IGH



ATM/p53



Probe for chromosome 13

Anita Kulharya

Electronically signed on
6/22/2011 3:58 PM by
Anita Kulharya, PhD
Cytogeneticist